Business Wire

Square Launches Integrated, Omnichannel Solutions For Businesses in France

21.9.2021 10:00:00 EEST | Business Wire | Press release

Share

Today Square, the globally trusted software, payments, and hardware solution for businesses of all sizes, launches in France. Following a successful Early Access Programme, now small businesses and large enterprises across France can access Square’s innovative ecosystem with the tools they need to start, run, grow, and adapt their businesses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005137/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Square Launches Integrated, Omnichannel Solutions For Businesses in France (Photo: Business Wire)

“I’ve been using Square’s products both on-site and online over the past few months and it has revolutionised how I run my business,” said Anne-Laure Fonrose, Founder of Tatie Nanna. “Having an integrated, omnichannel payment solution means our customers can pay in any way that suits them. It’s all been easy to set-up and run, the product looks great on site, and the connectivity is super-fast which helps avoid long queues. I’m proud to be using Square as we continue to grow our business.”

French businesses will now have access to a full stack of integrated business tools. Square’s suite of products are designed to seamlessly work with each other to save businesses time and money, reduce inefficiencies from managing multiple systems, and help sellers grow their businesses in the future. Additionally, Square offers fair, transparent, and merchant-friendly pricing for business software and payment processing without requiring any long-term contract or extra fees. Square takes care of fraud prevention, dispute management, security, and compliance at no additional cost. Square’s POS certification also enables merchants to comply with the “Loi anti-fraude TVA, 20181”. Businesses can access their funds as soon as the next working day and only pay a transaction fee when they accept a card or mobile payment.

“International growth has been a key priority this year, and we’re proud to officially launch in France as our third European market,” said Alyssa Henry, Executive Vice President at Square. “Sellers around the country will now be able to use our omnichannel ecosystem of products and services, allowing business owners to focus on running their business.”

“We are thrilled to expand Square’s solutions into France, helping merchants to run their entire business end-to-end with integrated software, hardware, and data analytics, while making it easier for them to take card payments,” said Jason Lalor, European Executive Director at Square. “French businesses can trust Square to be a fair, transparent, and innovative partner they can rely on to help them run their business and get back-on-track after times of uncertainty.”

French businesses can now sell online, in-person, or both with Square’s integrated suite of products, including:

  • Point of sale and payments software and hardware to suit any business: Square launches with two point of sale software products and three versatile payment terminals in France offering both mobile and brick & mortar businesses fully integrated POS software, reliable and secure payments acceptance, and one transparent processing rate of 1.65% for all card-present transactions. With no long-term contracts or monthly fees, the systems are designed for you and your employees to get started quickly.
    • Square Point of Sale is the trusted solution used by business owners around the world to process payments, sell anywhere, and manage their customer base. With fast checkout flows, built-in customer management, and intuitive sales reporting, Square Point of Sale makes it easy to run a business customers love.
    • Square for Restaurants helps businesses by offering an integrated set of industry-specific tools and POS for food and beverage merchants that would ordinarily require multiple vendors, all under one umbrella.
    • Square Terminal, Square Stand, and Square Reader are versatile, easy-to-set-up devices. For a limited time, Square Terminal will be priced at 99 € (usually 165 €), Square Stand will be 79 € (usually 139 €), and Square Reader will be completely free (usually 19 €) – all available on Square Shop. This pricing is limited to one device per merchant.
  • Square Online: Square’s fully integrated e-commerce platform that automatically syncs inventory and orders with any Square point of sale makes it seamless for any business to expand through omnichannel selling. Square Online supports sellers across a variety of verticals: from easily enabling click-and-collect for local business, to a QR code dining platform allowing diners to order and pay from their mobile device, to a full ecommerce website with social media integrations for retail. Square Online offers a feature-rich free plan as well as a variety of paid subscription plans and payment processing is competitively priced at 1.4% + 25c per transaction for EU cards.
  • Robust business tools to power operations: Square manages the behind-the-scenes details, giving time back to merchants to focus on running their business. Tools include:
    • Online Checkout, to quickly sell online via embeddable buy buttons and payment links
    • Virtual Terminal, to use your computer to take payments remotely
    • Team Management, to streamline timecards and staffing
    • Kitchen Display System, to expedite your kitchen operations – including delivery orders
    • eGift Cards, to provide an additional way to reach customers
    • Square Invoices will launch later this year to help businesses send professional, digital estimates and invoices and get paid faster
    • Partner platform to unlock even more functionality: Square integrates with business tools like Prestashop, Wix, Bookeo and Deliverect to enable businesses to use Square seamlessly with third-party software that caters to their specific needs.
    • Suite of API’s enabling developers to create solutions for sellers: Our APIs and SDKs enable developers to build custom applications that can seamlessly integrate with the rest of our ecosystem of products.

Businesses interested in learning more about getting started with Square can visit: https://squareup.com/fr

About Square, Inc.

Square, Inc. (NYSE: SQ) builds tools to empower businesses and individuals to participate in the economy. Sellers use Square to reach buyers online and in person, manage their business, and access financing. Individuals use Cash App to spend, send, store, and invest money. And TIDAL is a global music and entertainment platform that expands Square's purpose of economic empowerment to artists. Square, Inc. has offices in the United States, Canada, Japan, Australia, Ireland, Spain, Norway, and the UK.

www.squareup.com

1On 24 October 2018, the French Anti-Fraud Act1 (loi relative à la lutte contre la fraude, the Act) was published in the Official Journal (OJ). The Act was designed to strengthen the measures to fight against taxpayers’ failure to comply with their tax and social duties.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Daniela Karthaus
00353-896025037
press@squareup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye